State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou 510060, Guangdong, P.R. China.
Department of Ophthalmology, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, P.R. China.
Cell Metab. 2019 Sep 3;30(3):414-433. doi: 10.1016/j.cmet.2019.08.011.
In 2009, it was postulated that endothelial cells (ECs) would only be able to execute the orders of growth factors if these cells would accordingly adapt their metabolism. Ten years later, it has become clear that ECs, often differently from other cell types, rely on distinct metabolic pathways to survive and form new blood vessels; that manipulation of EC metabolic pathways alone (even without changing angiogenic signaling) suffices to alter vessel sprouting; and that perturbations of these metabolic pathways can underlie excess formation of new blood vessels (angiogenesis) in cancer and ocular diseases. Initial proof of evidence has been provided that targeting (normalizing) these metabolic perturbations in diseased ECs and delivery of metabolites deserve increasing attention as novel therapeutic approaches for inhibiting or stimulating vessel growth in multiple disorders.
2009 年,有人假设内皮细胞(EC)只有在相应地调整其新陈代谢的情况下,才能执行生长因子的指令。十年后,人们已经清楚地认识到,与其他细胞类型不同,EC 通常依赖于不同的代谢途径来生存和形成新的血管;单独操纵 EC 的代谢途径(甚至不改变血管生成信号)就足以改变血管发芽;这些代谢途径的干扰可能是癌症和眼部疾病中新生血管过度形成(血管生成)的基础。已经提供了初步证据,表明针对患病 EC 中的这些代谢干扰(使其正常化)以及代谢物的输送值得越来越多地关注,因为它们是抑制或刺激多种疾病中血管生长的新的治疗方法。